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ABSTRACT
The COVID-19 outbreak was declared a pan-
demic on March 2020. Many patients
with SARS-CoV-2 infection have underlying
chronic medical conditions such as diabetes,
cardiovascular disease (CVD), and hyperten-
sion. Patient-related outcomes are worse if there
are associated comorbidities. We do not have
enough evidence regarding the most appropri-
ate management of patients with diabetes dur-
ing COVID-19 infection. Insulin resistance and
CVD together increase the inflammatory state
of the body, which can contribute to and per-
haps mediate the increase of COVID-19 sever-
ity. Hence, in addition to management
of dysglycemia, other CVD risk factors should
be targeted. We explore the possible patho-
physiologic links between diabetes and COVID-
19 and discuss various options to treat dysg-
lycemia, hypertension, and dyslipidemia in the
era of COVID-19.
Keywords: Cardiovascular risk; COVID-19;
Diabetes; Diabetes management
Key Summary Points
Many patients with SARS-CoV-2
infection have underlying chronic
medical conditions.
Patient-related outcomes are worse if there
are associated comorbidities.
Insulin resistance and cardiovascular
disease contribute to the increased
severity of COVID-19.
Management of dysglycemia,
hypertension, and dyslipidemia should be
targeted individually in patients with
COVID-19 infection.
SARS-CoV-2 patients are vulnerable to the
development of thromboembolic disease.
A personalized approach to
antithrombotic/thromboembolism
prophylaxis is recommended.
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INTRODUCTION
In December 2019, severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) caused
clusters of patients with pneumonia in Wuhan,
Hubei Province, China [1, 2]. On 11 March
2020, the World Health Organization (WHO)
declared the COVID-19 outbreak a pandemic
[3]. To date, 5,103,006 confirmed cases and
333,401 deaths have been reported globally [4].
Many patients with COVID-19 have associated
comorbidities. Hypertension is reported in about
one-fifth of the patients, followed by diabetes in
9.7% and CVD in 8.4%. In addition, patients with
underlying comorbidity have more severe infec-
tions and worse clinical outcomes [5, 6]. In
another systematic review on risk factors of criti-
cal andmortal COVID-19, diabetes (OR 3.68, 95%
CI 2.68–5.03), CVD (OR 5.19, 95% CI 3.25–8.29),
and hypertension (OR: 2.72, 95% CI 1.60–4.64)
were significantly more prevalent in the critical
than non-critical group [7]. Higher case fatality
rates (CFR) have been reported in COVID-19
patients with CVD (13.2%), diabetes (9.2%), and
hypertension (9.2%), while the rate is 1.4% in
those with no comorbidities [8].
In this review, we will examine what is known
concerning the use of various classes of medica-
tions commonly used in the treatment of patients
with type 2 diabetes (T2DM) in the era of COVID-
19; this includes treatments of patients either
without or during active infection with SARS-
Cov-2 virus. It should be pointed out that some of
the recommendations detailed below are based
on the best judgment of physicians and endocri-
nologists with first-hand experience in the care of
such patients and not on results of extensive
clinical trial data. This article is based on previ-
ously conducted studies and does not contain any
studies with human participants or animals per-




Type 2 diabetes mellitus (T2DM) is a prevalent
diseaseglobally. Ithasbeenrecognizedasaprimary
risk factor for the development of severe pneu-
monia due to respiratory viral infections [9]. A
reciprocal interaction has been identified between
COVID-19 and diabetes. Angiotensin-converting-
enzyme 2 (ACE2) is recognized as the receptor for
the virus. Viral entry might be facilitated by
hyperglycemia, which upregulates ACE2 expres-
sion on cell surfaces of the pulmonary system [10].
SevereSARSCoV-1 infectionhasbeenassociated
with prolonged hyperglycemia in people without
pre-existing diabetes. Potential direct b-cell damage
caused by SARS-CoV-2 might lead to insulin defi-
ciency and worsening of hyperglycemia [11]. Fur-
thermore, hyperglycemia promotes the synthesis
and release of proinflammatory cytokines, leading
to oxidative stress, which mediates tissue inflam-
mation. Chronic inflammation might be among
the underlying mechanisms contributing to a
higherpropensity to infectionandworseoutcomes.
In addition, hyperglycemia is associated with
impaired lymphocyte proliferation and neutrophil
functions [12]. PatientswithCOVID-19 commonly
present with lymphocytopenia and leukopenia.
Lymphocytopenia has been shown to correlate
with prognosis in patients with COVID-19 [13].
Furthermore, inflammatory cytokines
including interleukin-6 (IL-6), C-reactive pro-
tein, and coagulation activity are increased in
COVID-19 infection [14]. They are also associ-
ated with the infection severity [15]. In T2DM,
the inflammatory response is enhanced and an
imbalance between coagulation and fibrinolysis
takes place, with increased levels of clotting
factors and endothelial dysfunction. Vascular
inflammation and endothelial dysfunction are
parts of other co-existing chronic conditions,
namely hypertension and CVD [16].
TREATMENT OF HYPERGLYCEMIA,
HYPERTENSION, AND OTHER CVD




Currently, we do not have enough evidence
regarding the most appropriate management of
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patients with diabetes during COVID-19 infec-
tion. People with T2DM might experience gly-
cemic decompensation. Hence, more frequent
blood glucose monitoring and rigorous glucose
control seem reasonable to avoid serious com-
plications. Moreover, selection of appropriate
treatment regimens needs careful considera-
tion. Although treatment of dysglycemia is the
main concern, the importance of other CVD
risk factors cannot be overemphasized.
Use of Insulin in Patients with COVID-19
There are not enough studies on the proper use
of insulin in patients with T2DM in the era of
COVID-19, and specifically once the patient has
become infected. As noted above, hyper-
glycemia per se stimulates ACE2 expression
and, as the ‘‘receptor’’ for the virus, it may play
an important role in mediating the severity of
COVID-19. It is also possible the overexpression
of ACE2 plays an important role in the apparent
increased susceptibility of patients with T2DM
to acquiring the infection. Insulin is commonly
used in the management of T2DM especially
when the disease has been well established and
the patient’s beta cells are ‘‘exhausted.’’ Of
course, in patients with T1DM, insulin use is
mandatory. Hence, insulin should continue to
be used prior to any infection with the aim of
achieving near-normal levels of glycemia safely.
In patients with diabetes who are admitted
to the hospital because of COVID-19, glycemic
management should be continued with close
monitoring. In addition to hyperglycemia of
diabetes, stress hyperglycemia, i.e., elevation of
glucose in the absence of diabetes that results
from elevated epinephrine and cortisol, appears
to play a critical role in increasing the severity
of the viral infection. Recently, Bode et al.
reported that stress hyperglycemia (with or
without diabetes) is highly correlated with the
severity of COVID-19 [17]. Their findings show
that stress hyperglycemia is far more commonly
associated with the severity of COVID-19 than
is the diagnosis of diabetes itself. Another recent
large study on hospitalized patients with
COVID-19 reported that the mortality of
patients with diabetes was significantly higher
in those whose blood glucose levels were poorly
controlled compared to patients with good
glycemic control [18]. Moreover, Sardu et al.
showed that in hospitalized patients with pre-
vious diabetes or those with stress hyper-
glycemia, insulin infusion was associated with
lower IL6 and d-dimer levels during hospital-
ization. They concluded that in-patient optimal
glucose control is associated with lower risk of
severe disease and death in patients with
COVID-19 [19].
Hence, it appears that insulin therapy with
close monitoring of blood glucose is essential to
achieving better outcomes in patients hospital-
ized with diabetes, hyperglycemia, and COVID-
19.
USE OF ORAL GLUCOSE-LOWERING
MEDICATIONS
Metformin
Metformin, a biguanide, was introduced in the
1950s as the first-line therapy in people with
type 2 diabetes. When used as monotherapy, it
can lower HbA1c by around 1.5% [20]. Met-
formin exerts its function via several cellular
pathways, including AMP-activated protein
kinase (AMPK). Metformin also reduces the
production of reactive oxygen species (ROS),
oxidative stress, and DNA damage [21]. In
addition to glycemic control, metformin was
used in patients with influenza and malaria
[22].
The SARS-CoV-2 entry into host cells is
mediated via binding to the membrane-bound
form of ACE2 followed by internalization of the
complex [23]. AMPK has been shown to increase
the expression and phosphorylation of ACE2
[24], a process that is potentiated by metformin.
Addition of a phosphate group causes confor-
mational and functional changes that could
theoretically lead to a decrease in SARS-CoV-2
binding to the receptor [25]. However, upregu-
lation of ACE2 diminishes the deleterious
effects of the proinflammatory cascade induced
by the renin-angiotensin-aldosterone system
(RAS) [26].
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Metformin exerts an inhibitory effect on the
mammalian target of rapamycin (mTOR) sig-
naling cascade [27]. It has been shown that
mTOR signaling plays an important role in the
pathogenesis of influenza [28].
In vitro and in vivo studies suggest that
metformin may have an inhibitory effect on
infections with hepatitis C and hepatitis B virus.
Increasing insulin sensitivity may be a mecha-
nism that enhances the clinical response to
antiviral therapy in chronic hepatitis C patients
[29]. Hence, metformin appears to be a safe and
effective medication for the fight against SARS-
CoV-2 in people with T2DM.
Dipeptidyl Peptidase 4 Inhibitors (DPP4i)
DPP4 is a transmembrane glycoprotein expres-
sed in many tissues, including immune cells. It
activates T cells, upregulates CD86 expression
on macrophages and B cells, and stimulates the
NF-jb pathway, thereby promoting inflamma-
tion. Moreover, DPP4 was found to be the same
as CD26, a cell surface glycoprotein. CD26 plays
an important role in immunology, autoimmu-
nity, and diabetes. In the context of glucose
hemostasis, DPP4 regulates glucagon-like pep-
tide 1 (GLP-1) biologic activity.
DPP4i are commonly used to treat patients
with T2DM. They increase insulin secretion via
endogenous GLP-1, an insulinotropic polypep-
tide [30, 31]. The effects of DPP4 inhibition on
the immune response in patients with T2DM
are controversial. It has been reported that the
risk of infection does not increase with DPP4i
compared to placebo or other glucose-lowering
drugs (OGLDs) [32]. Although there are some
concerns regarding the risk of nasopharyngitis
with treatment with DPP4i, they are not asso-
ciated with an increased risk of upper respira-
tory tract infection compared with other
OGLDs [33].
DPP4 acts as a functional receptor for MERS-
COV; however, there is no robust evidence that
it is a possible receptor for SARS-COV2 [30].
Since DPP4 plays a co-stimulatory role in T-cell
maturation and activation, DPP4 inhibition
could be associated with some degree of
immune suppression, reducing the risk of acute
respiratory complications [30, 31].
Sodium Glucose Transporter 2 Inhibitors
(SGLT2i)
SGLT2i demonstrated cardio- and renal-protec-
tive benefits in people with T2DM and an ele-
vated risk of cardiovascular disease [34–36].
They prevent the release of proinflammatory
cytokines and reduce lactate levels [37, 38]. This
might counterbalance the increased lactate
level due to cell destruction in COVID-19
infection. Moreover, SGLT2i increase the ACE2
level and as a consequence angiotensin 1–7, a
potent vasodilator [39].
The increased level of angiotensin 1–7 may
be protective against acute respiratory distress
syndrome (ARDS); however, dehydration
should be avoided to reduce the risk of eug-
lycemic diabetic ketoacidosis [40].
Thiazolidinediones (TZDs)
TZDs enhance the actions of insulin. Insulin
resistance is associated with elevated levels of
circulating inflammatory biomarkers.
The inflammatory process plays an impor-
tant role in the initiation and progression of
atherosclerosis [41].
However, COVID-19 infection triggers the
generation of proinflammatory cytokines and
chemokines [1]. It has been reported that res-
piratory failure is the cause of death in 70% of
fatal COVID-19 cases [42].
Animal studies demonstrated that pioglita-
zone decreases concentrations of circulating
ACE and Ang II and increases concentrations of
circulating ACE2 and Ang-(1–7). In addition, it
attenuates lung inflammation and fibrosis
[43, 44]. TZDs may positively affect cardiovas-
cular risk factors, including proinflammatory
markers, pro-thrombotic markers, and adhesion
molecules in T2DM. The anti-inflammatory
effect of TZDs ameliorates the prognosis of
COVID-19. Considering the potential risk of
heart failure with TZD, its probable benefits in
the treatment of people with T2DM and
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COVID-19 infection should be further
investigated.
Use of Glucagon-like Peptide Receptor
Agonist (GLP1RA)
Acute lung injury is one of the clinical charac-
teristics of patients with severe COVID-19
infections. GLP-1 receptors are present in sev-
eral organs including the lungs. It has been
shown that GLP1 exerts an anti-inflammatory
effect and improves surfactant release.
Lipopolysaccharide (LPS)-induced polymor-
phonuclear neutrophil (PMN) extravasation
and acute lung injury (ALI) have been shown to
be prevented by liraglutide, a GLP1RA in animal
models. It restores intercellular tight junctions,
prevents PMN-endothelial adhesion, and sup-
presses PMN migration [42]. The anti-inflam-
matory action of GLP1RA is mediated through
blockade of protein kinase C or nuclear factor-
kappa B (NF-jB) and the activation and subse-
quent expression of inflammatory cytokines. In
addition, it activates cAMP-induced adenosine
monophosphate-activated protein kinase
(AMPK), leading to anti-inflammatory effects on
monocyte adhesion [46].
Therefore, it could be hypothesized that
GLP-1 RA could alleviate the cascade of
inflammatory response and decrease lung injury
induced by SARS-CoV-2 infection [47].
MANAGEMENT OF HYPERTENSION
IN PATIENTS WITH DIABETES
DIAGNOSED WITH COVID-19
T2DM and insulin resistance are both associated
with hypertension. Multiple studies have
shown that the presence of hypertension is an
important comorbidity that is associated with
increases in the prevalence and severity of
COVID-19 [48]. A pooled analysis found that in
patients with COVID-19, HTN was associated
with a * 2.5-fold increase in the risk of severity
and mortality. Two different studies in China
showed that hypertension is the most prevalent
comorbidity in patients with COVID-19, being
present in 16.9% and 17.1% of patients with the
disease, respectively [6, 13]. Another recent
study conducted on 5700 patients hospitalized
with COVID-19 in New York City showed that
56.6% of the patients had hypertension [49].
High blood pressure can stimulate sympa-
thetic tone and increase oxidative stress and
inflammation, thereby contributing to greater
insulin resistance. Hypertension is also highly
associated with, and can lead to, cardiovascular
and renal disease [50]. Insulin resistance and
cardiovascular disease together increase the
inflammatory state of the body, which can
contribute to and perhaps mediate the
increased severity of COVID-19 [51].
USE OF ACE INHIBITORS AND ARBS
IN PATIENTS WITH DIABETES
AND COVID-19
Angiotensin-1, which is produced by the action
of renin on angiotensinogen, is converted to 8
amino-acid angiotensin-2 peptide by action of
angiotensin converting enzyme, ACE-1 (com-
monly referred to as ACE). Angiotensin-2 stim-
ulates aldosterone secretion, which causes
sodium retention and increases the BP. It also
stimulates the production of prostaglandins and
vascular endothelial growth factor (VEGF),
leading to increased vascular permeability,
especially in the lungs, thereby increasing the
risk of ARDS. Angiotensin-2 also stimulates the
release of inflammatory cytokines, which
increase the severity of COVID-19 [52, 53].
ACE-2, a membrane-bound enzyme that is
expressed in the lungs and many other tissues,
converts angiotensin-2 to angiotensin 1–7 [54].
Angiotensin 1–7 peptide has anti-inflammatory
properties and decreases insulin resistance; it
also causes vasodilation and increases vascular
blood flow [55, 56].
Some reports have suggested that the use of
ACE-1 inhibitors and angiotensin receptor
blockers (ARBs) may have deleterious effects on
patients with COVID-19 [57]. ACE-1 inhibitors
and ARBs are reported to upregulate ACE-2
expression [58–61].
ACE-2 serves as the ‘‘receptor’’ and the major
entry site of SARS-Cov-2 into the pulmonary
system; hence, upregulation of ACE-2 in the
3454 Adv Ther (2020) 37:3450–3462
lungs could lead to increased risk of contracting
COVID-19 and its expression in other tissues
(including the heart, kidneys, and pancreatic
islets), increasing the severity of disease once
infected [62–64]. On the other hand, ACE-2
activity results in increased synthesis and levels
of angiotensin 1–7. As noted, this seven amino-
acid peptide exhibits anti-inflammatory and
vasodilatory effects that could have highly
beneficial effects on harnessing the inflamma-
tion and ‘‘cytokine storm’’ that results from the
viral infection [54–57, 64].
Given the above, it seems important that the
balance between ACE-1 and ACE-2 activities
should be optimally maintained in patients
with COVID-19 [64]. Regulatory bodies and
associations including the American College of
Cardiology and American Heart Association
(ACC/AHA) have recommended continued use
of ACE-1 inhibitors and ARBs in patients with
COVID-19. Importantly, these medications are
commonly used in patients with heart failure,
and their withdrawal can have serious deleteri-
ous effects. Discontinuation of these medica-
tions can also lead to an increase or fall in blood
pressure when another suboptimal agent is used
as a substitute [57, 64, 65].
Despite the above, many patients with
T2DM who are treated with these medications
have no history of heart failure, and the agents
are used primarily for prevention of renal dis-
ease. This topic remains controversial, and
results of recent studies have shown conflicting
results [66, 67]. More detailed studies are nec-
essary to enlighten this topic. We recommend
patients should not stop or change this group of
medications.
USE OF CALCIUM CHANNEL
BLOCKERS AND COVID-19
Calcium channel blockers (CCBs) are com-
monly used in patients with hypertension. A
study conducted by Zhang et al. suggested that
CCBs might inhibit replication of SARS-CoV-2
virus inside cells by blocking calcium entry and
inhibiting their intracellular replication path-
way [67]. The elevated intracellular calcium can
also stimulate mitochondrial dysfunction,
leading to cell stress and apoptosis, which can
induce an inflammatory response [68]. Hence,
CCBs can have positive effects by decreasing
oxidative stress and inflammation by regulating
intracellular calcium in patients with T2DM
and hypertension [69]. Zhang et al. conducted a
retrospective study of 90 patients with COVID-
19 with hypertension as their sole comorbidity.
They studied patients who were being treated
with amlodipine besylate versus those using
other antihypertensive medications (including
ACEIs, ARBs, beta-blockers, and thiazide
diuretics) versus those not taking anti-hyper-
tensive medications. The case-fatality rate
showed a significant decrease from 26.1% in
patients not treated with amlodipine besylate
versus 6.8% in those being treated with
amlodipine besylate (P = 0.022) [66].
Based on the available data, CCBs may be
beneficial in patients with hypertension and
COVID-19. The mechanism appears to be in
part due to inhibition of replication of the virus
as well as to their anti-inflammatory effects [70].
Perhaps it is advisable to continue these medi-
cations once patients with T2DM become
afflicted with COVID-19. On the other hand, it
is important that most patients severely affected
with COVID-19 are hypotensive on admission
to the intensive care unit (ICU). More studies
are needed to inform judgment for the proper
use of these agents.
USE OF BETA-BLOCKERS
AND COVID-19
Beta blockers have been shown to reduce mor-
tality in patients with respiratory failure, ARDS,
and septic shock [71, 72]. Some studies suggest
that in patients with ARDS, B1-blockers reduce
pulmonary vascular flow without a negative
effect on systemic hemodynamics, and they
appear to decrease endothelial cell damage in
the lungs [73].
In addition to their antihypertensive effects
in patients with hypertension and COVID-19, it
is suggested that beta-blockers might be bene-
ficial at low doses in patients with normal blood
pressure and COVID-19 by inhibiting the sym-
pathetic system, which leads to a reduction in
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renin secretion by the kidneys. As noted above,
this can cause a downregulation of ACE2
receptors and decrease SARS-COV-2 entry into
the pulmonary cells [74]. In a study performed
on 12,500 individuals who were tested for
COVID-19 in New York City, people who were
taking beta-blockers had a lower likelihood for a
positive test for the virus [75]. Further studies
are necessary to determine the efficacy of beta
blockers in patients with COVID-19.
USE OF DIURETICS AND COVID-19
Patients with COVID-19 and hemodynamic
instability or sepsis are likely to need aggressive
fluid therapy as inpatients, and many patients
admitted with COVID-19 are hypotensive.
Consequently, they are vulnerable to adverse
outcomes of excessive fluid administration
leading to extravascular volume overload and
pulmonary edema [76]. Hence, fluid resuscita-
tion should be done very carefully with the goal
for cardiac output to become independent of
the preload [77].
Some studies evaluated the incidence of
acquiring COVID-19 and hospitalization in
patients taking diuretics in outpatient settings.
In a prospective cohort study on 406,793 par-
ticipants in the UK, 605 were diagnosed with
COVID-19. They evaluated the association of
use of antihypertensive medications in patients
with COVID-19 and the need for hospitaliza-
tion. Based on their multivariable model
adjusted for age, sex, ethnicity, and hyperten-
sion, loop diuretics were the only medications
that showed a positive significant relationship
to increased hospitalization with COVID-19
[78]. A cohort study from China including 610
patients with COVID-19 compared to 48,667
controls found that prior anti-hypertensive
medication therapy with ARBs and diuretics was
associated with lower risk of developing
COVID-19 [79]. Based on the available data, it is
clear that more studies are needed to be able to




WITH T2DM AND COVID-19
In patients with T2DM and in the era of COVID-
19, control of other comorbidities including
dyslipidemia and hypertension should be opti-
mized to the degree that is possible and safe
[80].
In patients with T2DM, dyslipidemia is pre-
sent in 30–60% of case and is characterized by
elevated triglyceride, moderately elevated dense
LDL and low HDL levels [81]. In these patients,
elevated plasma-free fatty acids released from
adipose tissue deposit in the liver and some are
secreted as VLDL, which leads to hypertriglyc-
eridemia. VLDL turns into smaller but dense
LDL particles by losing much of their triglyc-
erides; these denser LDLs in people with T2DM
are more atherogenic. Triglycerides also deposit
in peripheral tissues and lead to insulin resis-
tance. In addition, free fatty acids directly
stimulate Toll-like receptor 4 (TLR4) expressed
in immune system cells and can lead to cyto-
kine secretion and inflammation [51, 82–84].
It is well known that statins have anti-in-
flammatory effects that are independent of their
inhibition of HMG-CoA reductase activity. They
decrease the expression of TNF-a and other
proinflammatory cytokines including inter-
leukin-6 and -1 (IL-6 and IL-1) [85]. However,
the anti-inflammatory effect of statins can also
lead to upregulation of ACE2 expression [86].
Although increased ACE2 expression can
enhance the ability of the virus to enter host
cells and cause increased severity of infection in
COVID-19 [87], statins should not be discon-
tinued given the probability of a rebound
increase in interleukin IL-6 and IL-1. Hence, it is
generally recommended that statins be contin-
ued in patients with T2DM and COVID-19 [77].
Other lipid-lowering agents such as omega-3
and fibrates have anti-inflammatory effects also
independent of their lipid-lowering activity;
they directly reduce inflammatory markers such
as CRP and IL-6, 8 [88, 89]. The anti-inflam-
matory effects of omega-3 (n-3) polyunsatu-
rated fatty acids (n-3 PUFAs) decrease leukocyte
chemotaxis in certain dosages of
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eicosapentaenoic acid (EPA) plus docosahex-
aenoic acid (DHA) [90]. In addition, they also
decrease the production of inflammatory factors
including cytokines and chemokines by altering
the transcription factors NFj-B and PPAR-y that
regulate the expression of inflammatory genes
[88]. There is some evidence that fibrates are
effective for primary and secondary prevention
of CVD. They mainly reduce plasma triglyceride
and increase HDL levels by activating peroxi-
some proliferator-activated receptor (PPAR)-a
[91]; this leads to reduction in insulin resistance
in peripheral tissues.
There is a paucity of evidence to help inform
the proper use of lipid-lowering agents in
patients with T2DM who have developed
COVID-19. Nevertheless, based on the above
information, we recommended that statins and
other lipid-lowering medications be continued
in patients with T2DM. In cases where triglyc-
eride levels become extremely elevated during
the infection, more aggressive measures should
be taken to control the hypertriglyceridemia.
USE OF ANTIPLATELET/
ANTITHROMBOTIC MEDICATIONS
IN PATIENTS WITH T2DM
AND COVID-19
Several pathophysiologic mechanisms link
COVID-19 infection with thrombotic and
thromboembolic diseases. Systemic inflamma-
tion, cytokine storm, and hypoxia predispose
patients to thromboembolic events. On the
other hand, investigational therapies that are
currently used in treatment of these patients
might have drug interactions with antiplatelet
and antithrombotic medicines. Consequently,
the prothrombotic state might cause dissemi-
nated intravascular coagulation (DIC), venous
thromboembolism, and myocardial infarction
[92].
For patients who are taking antithrombotic
medicines, antithrombotic agents should be
continued. In the absence of any contraindica-
tion, venous thromboembolism prophylaxis
should be administered to all hospitalized
patients with COVID-19 infection without DIC.
Monitoring of biomarkers such as D-dimer is
not recommended to monitor anticoagulant
therapy. However, dose adjustment is necessary
for patients with moderate or severe COVID-19
and DIC, without overt bleeding, on chronic
anticoagulation [93].
CONCLUSION
SARS-CoV-2 infection is a global concern with a
high rate of both morbidity and mortality
especially in people who are at high cardiovas-
cular risk. There is currently not sufficient evi-
dence regarding the most appropriate
management of CVD risk in patients with dia-
betes during COVID-19 infection. Personalized
therapeutic strategies and optimal glucose con-
trol should be formulated based on age, disease
severity, and presence of diabetes-related
complications.
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